Is Atrion Corp Set to Continue its Rebound?

                 Is Atrion Corp Set to Continue its Rebound?

  PR Newswire

  MIAMI, January 23, 2013

MIAMI, January 23, 2013 /PRNewswire/ --

EmergingGrowth.com, a leading digital financial media company, Reports on
Atrion Corp. Discussion also includes Johnson & Johnson, Tyco International,
Baxter International, and Covidien Plc.

In the medical sector, so much attention is paid to massive, large-cap firms
like Johnson and Johnson (NYSE: JNJ) and Tyco International Ltd. (NYSE: TYC),
while smaller companies sometimes go by unnoticed. This gives you a great
chance to find undervalued stocks in the medical industry. Atrion Corp
(NASDAQ: ATRI) is one of these stocks.

Atrion Corp is a small cap company with a current value of about $379 million.
They produce medical devices and specialize in fluid delivery equipment for
cardiology and ophthalmology. This is a pretty niche market without a lot of
competition.

Baxter International Inc. (NYSE: BAX) and Covidien plc (NYSE: COV) make some
of the same products, but are also spread across many other medical fields. As
a result, Atrion has an advantage by being more specialized in its market and
has used this advantage to generate pretty steady cash flow and growth.

This paid off for investors. Atrion was able to deliver earnings per share
growth of at least 10% a year for the thirteen years between 1999 and 2011.
During this same period, Atrion took its share price from $8.00 a share to
nearly $250 a share in 2011. In a way, things were going nearly too smoothly
for this company.

In 2012, Atrion gave investors a scare when it reported negative growth in
both revenues and earnings. Its return on equity and return on assets also
fell by about 2-3%. This sparked a selloff that brought the share price to its
current level at $188. While the weak financial data is concerning, there's
good reason to believe investors oversold this stock.

Part of the reason why Atrion's margins fell is because it made a large share
repurchase at the end of 2011. This is an accounting issue and doesn't reflect
the performance of the company. Even with this drop, Atrion still has a very
healthy 29% operating margin and 20% profit margin.

Atrion also has a rock solid balance sheet. The company has no debt at this
time and is holding on to about $38 million in cash. It seems that the company
is building up its reserves while it looks for its next research development.
This is definitely smarter than rushing into a losing investment.

In the past, Atrion has shown that it knows how to make the most out of a new
opportunity. When it finally develops a new product, earnings should jump up.
In the meantime, Atrion is returning this extra money to its shareholders
through dividends and stock buybacks, most recently making a special $10.00 a
share dividend in November 2012.

For the short-run, there's no reason why Atrion's price should fall even
further. Instead, there's a good chance that it'll bounce back after it
delivers a few more quarters of solid earnings. For the future, it all depends
on whether Atrion can develop another winning product. Based on their track
record, I'm betting they will.

NEW: Feature your company on EmergingGrowth.com. Find out how by filling out
our referral form here… 
http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth

About EmergingGrowth.com

By offering 100% original and unmatched content by the best financial
reporters, writers and bloggers in the business, EmergingGrowth.com is
emerging as a leading digital financial media portal. Its services provide
users, subscribers and advertisers with a variety of content and tools through
a range of online, social media, mobile and other mobile outlets.

Since its inception, EmergingGrowth.com has distinguished itself from other
financial media companies with its sly approach to reading between the lines
in order to locate that needle in the haystack. Sign up today to see what
EmergingGrowth.com has to offer.

Disclosure

All information contained herein as well as on the EmergingGrowth.com website
is obtained from sources believed to be reliable but not guaranteed to be
accurate or all-inclusive. All material is for informational purposes only, is
only the opinion of EmergingGrowth.com and should not be construed as an offer
or solicitation to buy or sell securities. In addition, please make sure you
read and understand the Terms of Use , Privacy Policy and the Disclosure
posted on the EmergingGrowth.com website. Always remember that investing in
securities such as the ones listed within are for high-risk tolerant
individuals only and not the general public. Whether you are an experienced
investor or not, you should always consult with a stockbroker, financial
advisor, or similar before purchasing or selling any securities viewed on any
emails sent from EmergingGrowth.com or its website.

Join our Linked in Group… 
http://www.linkedin.com/groups/?gid=4650356&trk=hb_side_g

Like us on Facebook...
http://www.facebook.com/pages/EmergingGrowthcom/474647062557938

Contact: Contact: EmergingGrowth.com, info@EmergingGrowth.com, +1-305-323-5687
 
Press spacebar to pause and continue. Press esc to stop.